NewAmsterdam Pharma Company N.V. — 2023 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2023; quarterly figures below include the three months ended December 31, 2023. NewAmsterdam is a late-stage, clinical-stage biopharmaceutical company with no approved products. Its principal candidate is obicetrapib, an oral CETP inhibitor being developed for LDL-C lowering, alone and in a fixed-dose combination with ezetimibe. The financial statements are presented in U.S. dollars under U.S. GAAP; the company retrospectively recast prior periods from IFRS and euros, so comparisons with previously reported figures may differ.
Key financial metrics
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $14.1 million | $102.7 million |
| Research and development expense | $159.4 million | $86.7 million |
| Selling, general and administrative expense | $37.6 million | $19.5 million |
| Operating loss | $183.0 million | $3.6 million |
| Net loss | $176.9 million | $22.6 million |
| Net loss per share, basic and diluted | $2.15 | $1.19 |
| Net cash used in operating activities | $141.2 million | Net cash provided: $10.7 million |
| Cash at year-end | $340.5 million | $467.7 million |
| Total assets / total liabilities | $347.1 million / $58.7 million | $478.5 million / $48.4 million |
Q4 2023: Revenue was $0.8 million, operating expenses were $51.9 million, operating loss was $51.1 million, and net loss was $49.5 million ($0.60 per share). The filing does not provide a clear quarterly cash-flow value. Gross margin is not meaningful for this pre-commercial company; revenue principally reflects licensing-related income, not product sales. The balance sheet reports no conventional borrowings.
Material changes versus prior period
- Revenue fell 86%, chiefly because 2022 included $98.6 million of revenue recognized upfront for the Menarini license. 2023 revenue included a $5.4 million clinical milestone and $8.7 million recognized from deferred research and development consideration.
- R&D expense rose 84%, driven primarily by Phase 3 trial costs, manufacturing, and personnel. SG&A increased 93%, including higher personnel, public-company, and commercial-readiness costs.
- Net loss widened substantially as licensing revenue declined while operating expenses increased. Interest income of $11.3 million and a $5.1 million foreign-exchange gain partly offset expenses; fair-value remeasurement of warrants and earnout liabilities produced a $10.3 million loss.
- Cash declined by $127.3 million year over year. Operating cash use was partly offset by $8.9 million of financing proceeds, mainly warrant and option exercises.
Outlook, commentary, and risks
- Management said year-end cash was expected to fund operations through anticipated BROADWAY, BROOKLYN, TANDEM, and PREVAIL readouts. The company nevertheless expects significant ongoing losses and may need additional capital for subsequent development and commercialization.
- Expected clinical milestones at the time of filing: BROOKLYN top-line data in Q3 2024; BROADWAY in Q4 2024; TANDEM top-line data in Q1 2025; and PREVAIL cardiovascular-outcomes data in 2026. Management expected PREVAIL enrollment to finish in Q1 2024. These are forward-looking estimates, not guarantees.
- The company relies on obicetrapib’s clinical success and on third-party manufacturers and clinical-research providers. Key risks include trial failure or delay, regulatory approval, safety findings in larger studies, manufacturing or supply disruption, competition, reimbursement and pricing pressure, and the need for additional financing.
- Menarini has exclusive commercialization rights for licensed obicetrapib products in most European countries, if approved. The agreement provides potential development, regulatory, and commercial milestones of up to €863 million and tiered royalties; these amounts are contingent, not assured. The company plans to pursue U.S. commercialization itself if approved.
- After year-end, the company completed a February 16, 2024 offering of ordinary shares and pre-funded warrants, yielding net proceeds of $189.8 million. This is a subsequent event and was not included in December 31, 2023 cash.
- The company reported material weaknesses in internal control over financial reporting and concluded disclosure controls were not effective as of December 31, 2023. Remediation was underway but not complete. The auditor gave an unqualified opinion on the financial statements, but did not attest to internal-control effectiveness.
- The company disclosed an error in previously issued IFRS weighted-average share and loss-per-share figures for 2020–2022. The current U.S. GAAP statements present corrected share calculations; the filing says the U.S. GAAP statements are not a restatement of previously issued U.S. GAAP statements.
- Effective January 1, 2024, the company no longer qualified as a foreign private issuer, increasing U.S. reporting and compliance requirements. No material legal proceedings were reported.
Most important facts for investors to verify
- Progress, final results, safety data, and regulatory implications of the pivotal lipid trials and PREVAIL outcomes trial; confirm whether announced timelines remain achievable.
- Cash burn, financing needs, and the effect of the February 2024 offering and any subsequent share or warrant issuance on liquidity and dilution.
- Menarini milestone and royalty terms, amounts received to date, and the conditions required for future payments and European commercialization.
- Remediation and independent testing of the disclosed material weaknesses, and whether internal controls are judged effective in later filings.
- Reconcile reported historical comparisons against the recast U.S. GAAP figures, and assess potential dilution from options, warrants, and earnout shares.